Abdul-Azeez Muhammed Usman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdul-Azeez Muhammed Usman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Adam Friedman
SUNY Downstate University, Brooklyn, USA
1 shared publication - Adetayo Y. Odueke
University of Arkansas for Medical Sciences, Northwest Regional Campus, Fayetteville, USA
1 shared publication - Chukwuemeka Christian Aghasili
Geisinger Wyoming Valley Medical Center Wilkes‐Barre Pennsylvania USA
1 shared publication - David Onaolapo
First Cardiology Consultants Hospital, Lagos, Nigeria
1 shared publication - Francesco Rotatori
Richmond University Medical Center/Mount Sinai, Staten Island, USA
1 shared publication - Hakeem Adegboyega Popoola
Affiliation Department of Internal Medicine, Henry Ford Jackson Hospital, Jackson, Michigan, United States of America
1 shared publication
Latest Publications
- 30 August 2025
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (1) , 35-57
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction
Despite the well-established benefits of statin therapy in reducing atherosclerotic cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, necessitating alternative approaches. This review examines advances in non-statin lipid-lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid medications. We evaluate their mechanisms of action, clinical efficacy, and safety profiles on the basis of landmark trials. A conceptual framework for personalized lipid management is proposed, addressing residual cardiovascular risk, statin intolerance, and complex patient profiles. Clinical decision pathways are presented for high-risk patients, statin-intolerant individuals, and those with adherence challenges. We explore emerging therapies targeting novel pathways, including lipoprotein(a), apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) inhibitors, cholesteryl ester transfer protein (CETP) inhibitors, and gene-editing technologies. Implementation barriers, including cost considerations, insurance challenges, and global access disparities, are discussed alongside solutions.
- 30 August 2025
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (1) , 35-57
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction
Despite the well-established benefits of statin therapy in reducing atherosclerotic cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, necessitating alternative approaches. This review examines advances in non-statin lipid-lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid medications. We evaluate their mechanisms of action, clinical efficacy, and safety profiles on the basis of landmark trials. A conceptual framework for personalized lipid management is proposed, addressing residual cardiovascular risk, statin intolerance, and complex patient profiles. Clinical decision pathways are presented for high-risk patients, statin-intolerant individuals, and those with adherence challenges. We explore emerging therapies targeting novel pathways, including lipoprotein(a), apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) inhibitors, cholesteryl ester transfer protein (CETP) inhibitors, and gene-editing technologies. Implementation barriers, including cost considerations, insurance challenges, and global access disparities, are discussed alongside solutions.